Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Novo Nordisk Charts Signal Weakness Amid Wegovy Warning, Expert Says 'Could've Played Out VERY Differently If They Had Embraced $HIMS'

Weight-loss drugmaker Novo Nordisk A/S (NYSE:NVO)’s technical chart is displaying a largely bearish trend amid a profit warning issued by the company tied to its blockbuster obesity drug Wegovy. However, this expert believes that the Danish pharmaceutical giant could have avoided some trouble if it hadn’t ended its partnership with…

Benzinga

UnitedHealth Stock Drags on Dow: Stock Market Today

Corporate earnings have dominated Wall Street's attention this week, but that changes on Wednesday.

Kiplinger

What's Going On With Eli Lilly Stock On Tuesday?

Eli Lilly and Co. (NYSE:LLY) stock is trading lower on Tuesday after its weight loss drug rival, Novo Nordisk A/S (NYSE:NVO), trimmed its 2025 financial outlook.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Nordisk Cuts Earning Forecasts Again, Names New CEO

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday lowered its earning forecasts again as it unveiled a new chief executive to tackle "recent market challenges".

International Business Times

Ozempic and Wegovy maker Novo Nordisk sees shares tumble on profit alert

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

Evening Standard

Novo Nordisk shares plummet over 20% on weight-loss drug sale slump

The firm also named Maziar Mike Doustdar as its new CEO on Tuesday, after a gloomy financial forecast spooked investors.

Euronews

Novo Nordisk Implodes After Wegovy Warning—Is The Weight-Loss Bubble Bursting?

Novo Nordisk A/S (NYSE:NVO) suffered its worst trading session on record Tuesday, plunging as much as 25% in European markets after issuing a surprise profit warning tied to its blockbuster obesity drug Wegovy and appointing a new CEO.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Here’s What Happened the Last Time Novo Nordisk Stock Was This Oversold

NVO stock is plunging lower in premarket trading after slashing its guidance for 2025 again.

Barchart

Trump’s 15% tariff on medicines will harm patients, say EU drugmakers

Trade group says levy will reduce access, disrupt supply chains and cut R&D

The Guardian - UK

Ozempic And Wegovy Maker Cuts Outlook In Surprise Move, Picks New CEO

Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment Ozempic, experienced a significant downturn on Tuesday following the company’s decision to trim its 2025 financial outlook.

Benzinga

Weight-loss jab Wegovy sees another prescription boost after ban on copycats

Novo CEO ousted in May, in place until successor named

The Independent UK

Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China

In a letter to the U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide) and Eli Lilly and Co.’s (NYSE:LLY) Zepbound from flooding the market.

Benzinga

Judge Rules Mylan Did Not Infringe Novo Nordisk Patent In Wegovy Generic Case

The Novo Nordisk A/S (NYSE:NVO) attempt to block Mylan Pharmaceuticals from launching a generic version of its weight-loss drug Wegovy hit a major obstacle as the court ruled in Mylan's favor on key infringement claims related to U.S. Patent No. 9,764,003.

Benzinga

What's Going On With Hims & Hers Stock Wednesday?

Hims Hers Health, Inc. (NYSE:HIMS) shares are trading 16% higher Wednesday, adding to gains of more than 35% over the past month. Here’s a look at what’s going on.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'

As the Donald Trump administration plans up to 200% tariffs on pharmaceutical companies, Emily Field, head of European pharma research at Barclays, has said that it’s hard to predict which firm would be affected the most by these tariffs, except for Novo Nordisk A/S (NYSE:NVO).

MarketBeat

Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback

Hims & Hers stock dipped after Novo Nordisk pulled back its partnership for a weight loss drug distribution, though that may not mean much.

Bored Panda

40 People Who Decided To Stun The Internet By Sharing Their Pics After Using Ozempic For Weight Loss

40 pictures showing how people looked before and after choosing Ozempic as a weight loss solution.

The Guardian - UK

Denmark and Sweden’s Øresund bridge turns 25: have the benefits run in both directions?

While Copenhagen’s fortunes grow alongside rise in Swedish commuters over 16km bridge, benefits for Malmö are proving less obvious

Get all your
news in one place.

100's of premium titles.
One news app.

Euronews

‘Very obvious:’ Novo Nordisk may be illegally advertising Ozempic, says Spain’s health secretary

Spain is investigating Novo Nordisk over concerns it may be indirectly marketing its weight loss drugs. Euronews Health spoke to the country’s health secretary to find out more.

Benzinga

What's Going On With Hims & Hers Health Stock Today?

Hims Hers Health Inc. (NYSE:HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after selling off to start the week. Here’s a look at what you need to know.

Cycling News

George Hincapie's new Modern Adventure team: Renaissance or more of the same? - Opinion

Has the spectre of Lance Armstrong's doping evaporated or will it come back to haunt the new squad?

Benzinga

HIMS Crashes On Novo GLP-1 Fallout: Buy The Dip Or Bail?

Telehealth darling Hims Hers Health Inc (NYSE:HIMS) got slapped with a 34% stock crash on Monday. Novo Nordisk A/S (NYSE:NVO) ended their relationship – and it wasn't amicable.

International Business Times UK

Why Did Novo Nordisk Pull the Plug on Hims Collaboration?

Novo Nordisk ended its partnership with Hims & Hers on 23 June 2025, accusing the telehealth firm of selling unsafe, unapproved Wegovy knock-offs. Hims' stock tanked, and legal risks loom.

The Independent UK

World shares rally after Trump announces what appears to be a shaky Israeli-Iran ceasefire

Stock markets have rallied and oil prices fell after U.S. President Donald Trump announced what appears to be a shaky ceasefire in the Israel-Iran conflict

Benzinga

Hims CEO Slams Novo Nordisk For 'Anticompetitive Demands' After Ozempic Maker Abruptly Ends Partnership: 'We Refuse To Be Strong-Armed'

Hims Hers Health Inc. (NYSE:HIMS), CEO Andrew Dudum, has accused Novo Nordisk of exerting anticompetitive pressure to prioritize its weight-loss drug Wegovy over patient needs after the abrupt termination of its partnership with a pharmaceutical giant.

1 … 11 12 13 14

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.